Evidence map›Paper›PMID 34988891›Full record

ReviewMolecular biology reports2022

RNA sequencing and its applications in cancer and rare diseases.

Selvi Ergin, Nasim Kherad, Meryem Alagoz

Open access · bronzeAbstract readReview
In one paragraph

Review in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
11.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Targeted decontamination of sequencing data with CLEAN.NAR genomics and bioinformatics · 2025
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. RNA Sequencing in Disease Diagnosis.Annual review of genomics and human genetics · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Selvi ErginDepartment of Molecular Biology and Genetics, Biruni University, Istanbul, Turkey.
Nasim KheradDepartment of Molecular Biology and Genetics, Biruni University, Istanbul, Turkey.
Meryem AlagozDepartment of Molecular Biology and Genetics, Biruni University, Istanbul, Turkey. alameryem@hotmail.co.uk.ORCID http://orcid.org/0000-0002-6243-2146
Biruni University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the invention of RNA sequencing over a decade ago, diagnosis and identification of the gene-related diseases entered a new phase that enabled more accurate analysis of the diseases that are difficult to approach and analyze. RNA sequencing has availed in-depth study of transcriptomes in different species and provided better understanding of rare diseases and taxonomical classifications of various eukaryotic organisms. Development of single-cell, short-read, long-read and direct RNA sequencing using both blood and biopsy specimens of the organism together with recent advancement in computational analysis programs has made the medical professional's ability in identifying the origin and cause of genetic disorders indispensable. Altogether, such advantages have evolved the treatment design since RNA sequencing can detect the resistant genes against the existing therapies and help medical professions to take a further step in improving methods of treatments towards higher effectiveness and less side effects. Therefore, it is of essence to all researchers and scientists to have deeper insight in all available methods of RNA sequencing while taking a step-in therapy design.

Indexed as

NeoplasmsRare DiseasesExome SequencingHigh-Throughput Nucleotide SequencingHumansSequence Analysis, RNATranscriptomeEukaryotic organismsGene-related diseasesLong-readRNA sequencingShort-readTranscriptomes

Identifiers

PMID34988891
PMCPMC8731134
OpenAlexW4205984007

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.